ArticleGynecologic oncology reports2021
An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab.
Article in Gynecologic oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with sub-group analysis of potential prognostic factors.Clinics (Sao Paulo, Brazil) · 2025Pooled it
- Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases.Clinics (Sao Paulo, Brazil) · 2023Pooled it
- Successful treatment of recurrent epithelioid trophoblastic tumor (ETT) with pembrolizumab after pembrolizumab: A case report and review of literature in treatment of ETT.Gynecologic oncology reports · 2026Article
- Recurrent epithelioid trophoblastic tumor with complete response after surgery, chemotherapy, and immunotherapy: A case report and literature review.Gynecologic oncology reports · 2026Article
- Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity.Advances in therapy · 2026Review
- The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy.Journal of gynecologic oncology · 2025Article
- "Colon"ised by the unexpected: a case of extrauterine epithelioid trophoblastic tumour.Diagnostic pathology · 2025Article
- Immunotherapy in gestational trophoblastic neoplasia: advances and future directions.Frontiers in immunology · 2025Review
- The fertility-sparing treatment and outcome of epithelioid trophoblastic tumor isolated to lung: a case report and review literature.Frontiers in oncology · 2024Article
- Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm.Gynecologic and obstetric investigation · 2024Review
- Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature.Gynecologic oncology reports · 2023Article
- Postmenopausal mixed gestational trophoblastic neoplasia with complete response to immunotherapy - A case report.Gynecologic oncology reports · 2023Article
- Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases.Medical oncology (Northwood, London, England) · 2023Review
- Epithelioid trophoblastic tumor of the lower uterine segment and cervical canal: A case report.World journal of clinical cases · 2023Article
- Review
- Persistent trophoblastic atypia on endocervical curettage found to be an epithelioid trophoblastic Tumor: A case report and review of the literature.Gynecologic oncology reports · 2022Article
- Gestational trophoblastic neoplasia with extrauterine metastasis but lacked uterine primary lesions: a single center experience and literature review.BMC cancer · 2022Review
- Advances in immunotherapy and molecular targeted therapy of gestational trophoblastic tumor: current practice and future perspectives.American journal of cancer research · 2022Review
- Cytocompatibility of pH-sensitive, chitosan-coated FeFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of extrauterine epithelioid trophoblastic tumor (ETT)-the rarest variant of gestational trophoblastic tumor-that has been stable on nearly two years of pembrolizumab treatment. A 47-year-old gravida 2, para 2 who underwent a prophylactic bilateral salpingo-oophorectomy nine years prior and bilateral mastectomy five years prior in the setting of a strong family history of breast and ovarian cancer with no genetic testing performed, presented to an outside clinic with recurrent respiratory infections without resolution despite antibiotics. Radiology and pathology testing confirmed the ETT diagnosis, including a second opinion from the John I. Brewer Trophoblastic Disease Center of Northwestern University's Feinberg School of Medicine, and the patient was started on a chemotherapy regimen of etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin for seven cycles, with partial improvement in her disease. After PD-L1 testing showed the tumor had > 5% PD-L1 positivity, she initiated pembrolizumab in April 2019. CT imaging after three months revealed decreased lung, abdominal, and pelvic disease and she was continued on pembrolizumab. As of December 2020, she had completed 29 cycles of pembrolizumab, with a plan for her to continue treatment indefinitely given her decreased, but persistent, disease. Our findings suggest pembrolizumab is a reasonable option for treatment of patients with significant PD-L1 positivity on testing of the tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.